Antipsychotic Side Effects: Common, Serious & Long-Term
Antipsychotic medications commonly cause sedation, weight gain, and metabolic changes, with serious risks including tardive dyskinesia and neuroleptic malignant syndrome. Long-term use requires regular monitoring of movement, weight, blood sugar, and lipids, and these medications carry an FDA black box warning for increased mortality in elderly patients with dementia.
Overview
Antipsychotic medications — also called neuroleptics — are used primarily to treat schizophrenia, bipolar disorder, and as adjunctive therapy in major depressive disorder. Second-generation (atypical) antipsychotics such as aripiprazole (Abilify), quetiapine (Seroquel), olanzapine (Zyprexa), and risperidone (Risperdal) have largely replaced first-generation agents due to a lower risk of some movement-related side effects, though they introduce their own significant metabolic concerns.
Understanding the side effect profile of antipsychotics is essential for patients and caregivers. These medications can cause meaningful changes in weight, metabolism, movement, and hormonal function. Side effects vary by specific agent, dose, duration, and individual patient factors.
Common Side Effects
Mechanism
Most antipsychotic side effects stem from dopamine D2 receptor blockade throughout the brain and body, as well as antagonism at histamine H1, muscarinic, and adrenergic receptors. The broader the receptor-binding profile, the wider the range of side effects.
- Sedation and drowsiness — especially with quetiapine and olanzapine due to strong H1 blockade; often improves after the first few weeks
- Weight gain — significant with olanzapine and quetiapine; aripiprazole is associated with less weight gain; driven by H1 antagonism and metabolic disruption
- Metabolic changes — elevated blood glucose and lipids, independent of weight gain; olanzapine carries the highest risk
- Dizziness and orthostatic hypotension — caused by alpha-1 adrenergic blockade; most pronounced when standing up quickly
- Constipation and dry mouth — from anticholinergic (muscarinic) blockade, particularly with clozapine and olanzapine
- Akathisia — an uncomfortable sensation of inner restlessness and inability to sit still; can be distressing and is sometimes mistaken for worsening psychiatric symptoms
Serious Side Effects
⚠ The following serious adverse effects require immediate medical attention. Contact your prescriber or go to an emergency room if you experience symptoms of NMS, severe movement disorders, or irregular heartbeat.
Tardive Dyskinesia (TD)
Tardive dyskinesia is a movement disorder characterized by involuntary, repetitive movements — most commonly lip smacking, tongue thrusting, grimacing, or writhing movements of the limbs. It develops after prolonged exposure to dopamine-blocking medications and may be irreversible even after the drug is discontinued. All antipsychotics carry this risk, though second-generation agents have a lower rate than first-generation. The FDA has approved valbenazine (Ingrezza) and deutetrabenazine (Austedo) specifically for treating TD.
Neuroleptic Malignant Syndrome (NMS)
NMS is a rare but potentially fatal reaction involving a triad of high fever, severe generalized muscle rigidity, and altered consciousness, accompanied by autonomic instability (fluctuating blood pressure, rapid heartbeat, sweating). It can develop at any point during treatment. NMS requires immediate discontinuation of the antipsychotic and emergency medical management.
QT Prolongation
Several antipsychotics — particularly ziprasidone and haloperidol, but also quetiapine at higher levels — can prolong the QT interval on an ECG, increasing the risk of a dangerous heart rhythm called torsades de pointes. Risk is higher when combined with other QT-prolonging medications or in patients with underlying heart conditions.
Agranulocytosis (Clozapine)
Clozapine carries a unique and serious risk of agranulocytosis — a potentially fatal drop in white blood cell count that impairs the immune system's ability to fight infection. This is why clozapine is only available through a restricted Risk Evaluation and Mitigation Strategy (REMS) program requiring regular blood count monitoring.
Post-Injection Delirium/Sedation Syndrome (PDSS)
Olanzapine long-acting injection (Zyprexa Relprevv) carries a risk of PDSS, a serious adverse event where patients may experience sudden sedation, confusion, and delirium shortly after injection. Patients must be monitored in a healthcare setting for at least 3 hours after each injection.
Long-Term Effects
- Tardive dyskinesia risk accumulates — the longer someone takes an antipsychotic, the greater the cumulative risk of developing TD; annual screening is recommended
- Metabolic syndrome — chronic weight gain, dyslipidemia, and insulin resistance can increase cardiovascular risk over time; olanzapine carries the highest long-term metabolic burden
- Prolactin elevation — risperidone and paliperidone are strong prolactin elevators, which can cause menstrual irregularities, sexual dysfunction, galactorrhea (milk production), and reduced bone density over time
- Cognitive effects — long-term high-dose use may affect cognitive function, though the evidence is complex and confounded by the underlying psychiatric conditions
- Cataracts — quetiapine has been associated with lens changes in animal studies; periodic eye exams are recommended with long-term use
Who Is Most at Risk
- Elderly patients — increased sensitivity to sedation, falls, orthostatic hypotension, and cognitive effects; higher risk of movement disorders
- Patients with pre-existing metabolic conditions — diabetes or obesity may be worsened by antipsychotic-induced metabolic effects
- Those on high cumulative doses or long-duration treatment — tardive dyskinesia risk correlates with total lifetime exposure
- Patients with cardiac conditions — QT prolongation risk is amplified with underlying heart disease or concurrent QT-prolonging drugs
- Women — more susceptible to prolactin-related effects including menstrual changes and bone loss with risperidone
Antipsychotic medications are not approved for the treatment of dementia-related psychosis. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. This warning applies to all antipsychotic agents.
Managing Side Effects
Many antipsychotic side effects can be minimized or managed with proactive strategies. Discuss these options with your prescriber rather than stopping your medication abruptly.
- Weight and metabolic monitoring — baseline and regular measurement of weight, waist circumference, fasting glucose, and lipid panel is standard practice; dietary and exercise counseling should be part of any antipsychotic treatment plan
- Switching medications — if metabolic effects or weight gain are problematic, switching to an agent with a lower metabolic burden (e.g., aripiprazole or ziprasidone) may help
- Managing sedation — taking the full dose at bedtime can reduce daytime sleepiness; sedation often diminishes over the first few weeks
- Akathisia treatment — beta-blockers (propranolol), benzodiazepines, or dose reduction may help; do not ignore akathisia as it can significantly impair quality of life
- TD monitoring — the Abnormal Involuntary Movement Scale (AIMS) should be performed at baseline and at regular intervals; early detection allows for intervention before movements become severe
- Prolactin management — switching to a prolactin-sparing agent like aripiprazole may resolve prolactin-related side effects
Frequently Asked Questions
What is the most serious long-term side effect of antipsychotics?
Tardive dyskinesia (TD) is among the most serious long-term risks. It causes involuntary, repetitive movements — most commonly of the face and tongue — and may be irreversible even after the medication is stopped. Risk increases with longer duration of use and higher cumulative doses.
Do all antipsychotics cause weight gain?
Most antipsychotics carry some risk of weight gain, but the degree varies significantly. Olanzapine and clozapine tend to cause the most weight gain. Aripiprazole and ziprasidone are associated with less weight gain. Regular monitoring of weight and metabolic parameters is recommended for all patients on these medications.
What is neuroleptic malignant syndrome (NMS) and how serious is it?
Neuroleptic malignant syndrome is a rare but potentially life-threatening reaction to antipsychotic medications. It involves high fever, severe muscle rigidity, altered consciousness, and autonomic instability. NMS requires immediate emergency medical treatment and discontinuation of the antipsychotic.
Why are antipsychotics considered dangerous for elderly patients with dementia?
The FDA requires a black box warning on all antipsychotics regarding use in elderly patients with dementia-related psychosis. Clinical studies showed an increased risk of death — primarily from cardiovascular events and infections — in this population. Antipsychotics are not approved for treating dementia-related behavioral disturbances.
Related Drugs
⚠ This article is for informational purposes only and does not constitute medical advice. Never stop or adjust an antipsychotic medication without guidance from your prescriber — abrupt discontinuation can cause serious withdrawal effects and relapse of psychiatric symptoms.